drugset
drugset / Trial / NCT04416126

Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

NCT04416126 ↗

Phase 1 Completed 30 enrolled Arcturus Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-810 in healthy adult subjects.

Timeline

Start
2020-06-01
Primary completion
2020-12-09
Completion
2020-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ARCT-810 Messenger RNA (mRNA) — Intravenous

Indications

ornithine carbamoyltransferase deficiency